Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q1 2023 Earnings Presentation
19 slides from Expres2ion Biotech Holding Ab's earnings presentation, May 16, 2023
Slide 1: Presentation of Q1 2023 results
E X P R E S2 I O N BIOTECHNOLOGIES Click to edit Master title style Presentation of Q1 2023 results Innovative vaccines for a healthier world 16 May 2023 Hosted by E X P R E S2 I O N BIOTECHNOLOGIES ExpreS2ion Biotech Holding AB Org. Nr. 559033-3729 Innovative vaccines for a healthier world
Slide 2: Disclaimer
E X P R E S2 I O N BIOTECHNOLOGIES Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shal
Slide 3: Investment Highlights
E X P R E S2 I O N BIOTECHNOLOGIES Investment Highlights Leader in advanced protein sciences with novel pipeline addressing multi-billion € markets High-potential pipeline of key focus within infections diseases and oncology, backed up by strong intellectual property rights. Targeting sizeable unmet
Slide 4: Pipeline: Focus programs
E X P R E S2 I O N BIOTECHNOLOGIES Pipeline Focus programs Pre-clinical Market potential Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Partner / funding > 30 billion EUR COVID-19 ABNCoV2/SARS-CoV-2 cVLP > 10 billion EUR BREAST CANCER ES2B-C001/Her2 cVLP 100% Expr
Slide 5: Pipeline: Legacy programs
E X P R E S2 I O N BIOTECHNOLOGIES Pipeline Legacy programs Pre-clinical Market potential Disease Project / Target Discovery Pharmacology cGMP / Tox Phase 1 Phase 2 Phase 3 Partner / Funding >1.8 billion EUR MALARIA 1: Blood-Stage RH5 MultiViVax 2: Blood-Stage RH5-VLP 3: Transmission Pfs 48/45 Optim
Slide 6: ABNCoV2 – Next generation COVID-19 vaccine
CORONAVIRUS COVID-19 E X P R E S2 I O N ABNCoV2 – BIOTECHNOLOGIES Next generation COVID-19 vaccine Strong boosting effect across Durability across variants of concern variants of concern High level of protection – Stability at room temperature no need for adjuvant Similar increase in NAbs for Wuhan
Slide 7: Partnership with Bavarian Nordic
CORONAVIRUS E X P R E S2 I O N BIOTECHNOLOGIES Partnership with Bavarian Nordic ABNCoV2 is out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receives from Bavarian Nordic ExpreS2ion receives from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVa
Slide 8: ES2B-C001
BREAST CANCER E X P R E S2 I O N BIOTECHNOLOGIES ES2B-C001 Progressing rapidly toward clinical trial application Latest non-clinical developments Completed • Proof-of-concept non-clinical package • In vivo dose range finding studies in animal models Ongoing • Pivotal GLP safety study in a qualified
Slide 9: ES2B-C001: CMC update
BREAST CANCER E X P R E S2 I O N BIOTECHNOLOGIES ES2B-C001 CMC (chemistry, manufacturing and controls) update cVLP manufacturing • Completed for Phase I clinical trial • Ongoing stability studies Combined product • Completed engineering run (drug substance and drug product) • Continuation of viral c
Slide 10: ES2B-C001: Clinical development executing pre-launch activities
BREAST CANCER E X P R E S2 I O N BIOTECHNOLOGIES ES2B-C001 Clinical development executing pre-launch activities • First-in-human study aligned with DKMA ahead of CTA Regulatory submission • Necessary project management, regulatory and external consultant expertise in place Clinical development • Cli
Slide 11: Advancing towards key catalysts
E X P R E S2 I O N BIOTECHNOLOGIES Advancing towards key catalysts 2022 2023 2024 2025 ✓ ✓ BN Phase II 12-month durability data BN BN Phase II trial BN Phase III trial Phase III initial readout Expected royalties readout H1 initiation Q3 from sales COVID-19 BN initiating rolling submission ABNCoV2 B
Slide 12: Financials
E X P R E S2 I O N BIOTECHNOLOGIES Financials 12 Innovative vaccines for a healthier world 12
Slide 13: Operating Income
FINANCE E X P R E S2 I O N BIOTECHNOLOGIES Operating Income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6,000 6,000 6,000 Net sales Other operating income 5,000 5,000 5,000 = + 4,000 4,000 4,000 3,000 3,000 3,000 2,000 2,000 2,000 1,000 1,000 1,000 0 0 0 1Q20 3
Slide 14: Operating Costs
FINANCE E X P R E S2 I O N BIOTECHNOLOGIES Operating Costs Operating costs, SEK ‘000s R&D costs (external), SEK ‘000s 0 0 -8,000 -5,000 -16,000 -10,000 -24,000 -15,000 -32,000 -20,000 -40,000 -25,000 -48,000 -30,000 -56,000 -35,000 -64,000 -40,000 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 1Q23 4Q20 1Q21 2Q21 3Q
Slide 15: Profit / Loss for the Period
FINANCE E X P R E S2 I O N BIOTECHNOLOGIES Profit / Loss for the Period 1Q profit / loss, SEK ‘000s 2022 2023 0 -7,000 -14,000 -13,836 +90% -21,000 -26,308 -28,000 Innovative vaccines for a healthier world 15
Slide 16: Cash Development Year-to-Date
FINANCE E X P R E S2 I O N BIOTECHNOLOGIES Cash Development Year-to-Date SEK millions 120 111 1 100 80 1 72 -41 60 40 20 0 December 2022 New Capital Operations and Investment Activities Currency changes March 2023 Innovative vaccines for a healthier world 16
Slide 17: Cash Balance, 2019 – 1Q 2023 Quarterly
FINANCE E X P R E S2 I O N BIOTECHNOLOGIES Cash Balance, 2019 – 1Q 2023 Quarterly SEK millions 180 168 160 150 142 139 140 125 120 111 107 108 100 83 80 72 60 40 30 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 Innovative vaccines for a healt
Slide 18: Shareholder Composition
FINANCE E X P R E S2 I O N BIOTECHNOLOGIES Shareholder Composition ~13,000 shareholders holding ~37.6 million shares at end of Q1 No. of shareholders, No. of shares outstanding including brokers 16,000 40,000,000 14,000 35,000,000 12,000 30,000,000 10,000 25,000,000 8,000 20,000,000 6,000 15,000,000
Slide 19: Thank you
E X P R E S2 I O N BIOTECHNOLOGIES Thank you info@expres2ionbio.com Innovative vaccines for a healthier world 19
ExpreS2ion Biotech Holding — Q1 2023 Earnings Presentation on 6ix